GH Research PLC
GHRS
Positions held
Your positionsGHRS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- GH Research PLC operates in the biotechnology sector, which is known for its potential to innovate and address unmet medical needs, attracting significant investor interest.
- The company's current ratio stands at 28.696, indicating a strong liquidity position to cover short-term obligations.
- GHRS has a market capitalization of approximately $1.48 billion, suggesting it is a notable player in its industry.
- The company has reported a consistent net income loss, with -15.146 million in Q2 2026, highlighting ongoing financial challenges.
- GH Research has not generated any revenue in the last several quarters, with a total net income loss of -48.258 million for the year 2025.
- The stock has a 'Strong Sell' signal with a score of -16.00, indicating negative market sentiment and technical indicators.
Fundamentals
| Market cap | $1.40B | Enterprise value | $1.04B | Trailing P/E | — | Forward P/E | -11.05 |
| PEG | — | Price / book | 3.90 | Beta | 1.33 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -18.8% | ROA | -13.0% | Debt / equity | 0.00 |
| Current ratio | 28.70 | Free cash flow | -$36.52M | Analyst recommendation | none | Mean target | $42.89 |
| 52w high | $31.44 | 52w low | $12.04 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$15.1M | -$19.0M | -$14.1M | -$14.0M | -$9.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$19.4M | -$18.7M | -$16.7M | -$16.5M | -$14.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$48.3M | -$39.0M | -$35.6M | -$22.5M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$60.7M | -$50.2M | -$41.2M | -$30.7M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-06 · GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-02 · Is GH Research (GHRS) Trading At A Premium To Fair Value?
2026-07-27 · Wells Fargo Initiates GH Research at Overweight With $44 Price Target
2026-07-16 · Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug
2026-07-16 · Why Psychedelic stocks are surging today
2026-07-16 · GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS)
2026-07-13 · Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
Price (daily)
Full chart · RSI · MACD · patterns